Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study
Restricted accessResearch articleFirst published online March, 2017
Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study
A task force of scientists at the International Congress on Antiphospholipid Antibodies recognized that phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) might contribute to a better identification of antiphospholipid syndrome (APS). Accordingly, initial and replication retrospective, cross-sectional multicentre studies were conducted to ascertain the value of aPS/PT for APS diagnosis.
Methods
In the initial study (eight centres, seven countries), clinical/laboratory data were retrospectively collected. Serum/plasma samples were tested for IgG aPS/PT at Inova Diagnostics (Inova) using two ELISA kits. A replication study (five centres, five countries) was carried out afterwards.
Results
In the initial study (n = 247), a moderate agreement between the IgG aPS/PT Inova and MBL ELISA kits was observed (k = 0.598). IgG aPS/PT were more prevalent in APS patients (51%) than in those without (9%), OR 10.8, 95% CI (4.0–29.3), p < 0.0001. Sensitivity, specificity, positive (LR+) and negative (LR–) likelihood ratio of IgG aPS/PT for APS diagnosis were 51%, 91%, 5.9 and 0.5, respectively. In the replication study (n = 214), a moderate/substantial agreement between the IgG aPS/PT results obtained with both ELISA kits was observed (k = 0.630). IgG aPS/PT were more prevalent in APS patients (47%) than in those without (12%), OR 6.4, 95% CI (2.6–16), p < 0.0001. Sensitivity, specificity, LR + and LR– for APS diagnosis were 47%, 88%, 3.9 and 0.6, respectively.
Conclusions
IgG aPS/PT detection is an easily performed laboratory parameter that might contribute to a better and more complete identification of patients with APS.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
ArvieuxJDarnigeLCaronCReberGBensaJCColombMG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulant. Thromb Haemost1995; 74: 1120–1125.
4.
GalliMBerettaGDaldossiMBeversEMBarbuiT. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost1997; 77: 486–491.
5.
AtsumiTIekoMBertolacciniML. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum2000; 43: 1982–1993.
6.
TincaniAMorozziGAfeltraA. Antiprothrombin antibodies: A comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol2007; 25: 268–274.
7.
BertolacciniMLAtsumiTKoikeTHughesGRKhamashtaMA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost2005; 93: 289–297.
8.
PengoVBiasioloABroccoTTonettoSRuffattiA. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost1996; 75: 721–724.
9.
VaaralaOPuurunenMManttariMManninenVAhoKPalosuoT. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost1996; 75: 456–459.
10.
HorbachDAvan OortEDondersRCDerksenRHde GrootPG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost1996; 76: 916–924.
11.
ForastieroRRMartinuzzoMECerratoGSKordichLCCarrerasLO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost1997; 78: 1008–1014.
12.
PalosuoTVirtamoJHaukkaJ. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men – a nested case-control study. Thromb Haemost1997; 78: 1178–1182.
13.
BertolacciniMLAtsumiTKhamashtaMAAmengualOHughesGR. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol1998; 25: 1104–1108.
14.
GalliM. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome?J Autoimmun2000; 15: 101–105.
15.
DonohoeSMacKieIJIsenbergDMachinSJ. Anti-prothrombin antibodies: Assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol2001; 113: 544–549.
16.
GalliMLucianiDBertoliniGBarbuiT. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood2003; 102: 2717–2723.
17.
ZanonESaggioratoGRamonRGirolamiAPagnanAPrandoniP. Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost2004; 91: 255–258.
18.
TsutsumiAHayashiTChinoY. Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: Clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays. Mod Rheumatol2006; 16: 158–164.
19.
HoxhaARuffattiAPittoniM. The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome. Clin Chim Acta2012; 413: 911–913.
20.
GalliMBorrelliGJacobsenEM. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood2007; 110: 1178–1183.
21.
SciasciaSSannaGMurruVRoccatelloDKhamashtaMABertolacciniML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost2014; 111: 354–364.
22.
ForastieroRMartinuzzoMPomboG. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost2005; 3: 1231–1238.
23.
BizzaroNGhirardelloAZampieriS. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: A 15-year longitudinal study. J Thromb Haemost2007; 5: 1158–1164.
24.
AtsumiTKoikeT. Antiprothrombin antibody: Why do we need more assays?Lupus2010; 19: 436–439.
25.
ŽigonPAmbrožičAČučnikSKvederTRozmanBBožičB. Modified phosphatidylserine-dependent antiprothrombin [corrected] ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies. Clin Chem Lab Med2011; 49: 1011–1018.
26.
ŽigonPČučnikSAmbrožičAŠodin SemrlSKvederTBožičB. Antibodies to phosphatidylserine/prothrombin complex as an additional diagnostic marker of APS?Lupus2012; 21: 790–792.
27.
ŽigonPČučnikSAmbrožičA. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol2013; 2013: 724592.
28.
BertolacciniMLAmengualOAtsumiT. ‘Non-criteria’ aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus2011; 20: 191–205.
29.
BertolacciniMLAmengualOAndreoliL. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev2014; 13: 917–930.
30.
HoxhaARuffattiATonelloM. Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus2012; 21: 787–789.
31.
BertolacciniMLSciasciaSMurruVGarcia-FernandezCSannaGKhamashtaMA. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. Thromb Haemost2013; 109: 207–213.
32.
NojimaJIwataniYSuehisaEKuratsuneHKanakuraY. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica2006; 91: 699–702.
33.
TseliosKSarantopoulosAGkougkourellasIBouraP. The role of anti-phosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patients. Front Neurol2013; 4: 66.
34.
ZigonPPerdan PirkmajerKTomsicM. Anti-Phosphatidylserine/Prothrombin antibodies are associated with adverse pregnancy outcomes. J Immunol Res2015; 2015: 975704.
35.
GalliMLucianiDBertoliniGBarbuiT. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood2003; 101: 1827–1832.
36.
DevreeseKPeerlinckKHoylaertsMF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood2010; 115: 870–878.
37.
de LaatHBDerksenRHUrbanusRTRoestMde GrootPG. Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood2004; 104: 3598–3602.
38.
HeikalNMJaskowskiTDMalmbergELakosGBranchDWTeboAE. Laboratory evaluation of anti-phospholipid syndrome: A preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort. Clin Exp Immunol2015; 180: 218–226.
39.
SanfelippoMJoshiASchwartzSMeisterJGoldbergJ. Antibodies to phosphatidylserine/prothrombin complex in suspected antiphospholipid syndrome in the absence of antibodies to cardiolipin or beta-2-glycoprotein I. Lupus2013; 22: 1349–1352.
40.
HoxhaARuffattiAMattiaE. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med2015; 53: 1265–1270.
41.
AmengualOHoritaTBinderW. Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies. Rheumatol Int2014; 34: 1225–1230.
